AbbVie and Genmab reported a Phase 3 win for Epkinly (Genmab’s bispecific antibody) in newly diagnosed diffuse large B-cell lymphoma. The combination with R-CHOP cut the risk of disease progression or death nearly in half versus R-CHOP alone. In the trial of 900 patients at intermediate or high risk of death, Epkinly delivered a 51% relative risk reduction, exceeding investor expectations and outperforming a Roche comparator in cross-trial context. The companies framed the data as a step toward standard approval in first-line DLBCL, following Epkinly’s accelerated approval in the third-line setting. With Genmab also reporting $312 million in global net sales for Epkinly in the first half of the year, the Phase 3 results intensify the competitive threat to Roche’s Polivy in frontline lymphoma treatment.